

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A biodegradable neurotoxin implant, comprising: a neurotoxin component associated with; a biodegradable polymer component; and an acidity regulating component effective in ~~for~~ establishing in vivo a pH in the vicinity of the neurotoxin component associated with the implant of less than about 7, wherein the acidity regulating component comprises a monomer and an oligomer derived from the same biodegradable polymer.
2. (Original) The implant of claim 1, wherein the neurotoxin component comprises a Clostridial neurotoxin.
3. (Original) The implant of claim 1, wherein the neurotoxin component comprises a botulinum toxin.
4. (Original) The implant of claim 1, wherein the neurotoxin component comprises a botulinum toxin selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F, and G, and mixtures thereof.
5. (Original) The implant of claim 1, wherein the implant comprises an amount of a botulinum toxin between about 1 unit and about 500,000 units.
6. (Original) The implant of claim 1, wherein the implant comprises an amount of a botulinum toxin type A between about 10 units and about 2000 units.

7. (Currently Amended) The implant of claim 1, wherein the biodegradable polymer component is effective in controlling release of the neurotoxin from the implant when the implant is located in a patient's body.
8. (Original) The implant of claim 1, wherein the biodegradable polymer component includes a polymer selected from the group consisting of polyesters, poly(ortho esters), and polyanhydrides, and mixtures thereof.
9. (Original) The implant of claim 1, wherein the biodegradable polymer component comprises at least one polymer selected from the group consisting of polylactic acid (PLA), poly(lactide-co-glycolide) acid (PLGA), poly-L-lactic acid (PLLA), polycaprolactone, and poly(ortho acetate), and mixtures thereof.
10. (Original) The implant of claim 1, wherein the biodegradable polymer component includes a polymer that includes at least one ester bond, and biodegradation of the polymer occurs by hydrolysis of the at least one ester bond.
11. (Currently Amended) The implant of claim 1, wherein the acidity regulating component is provided in an amount effective in maintaining a pH of the implant to a value less than about 7 when the implant is located in a patient's body.
12. (Original) The implant of claim 1, wherein the acidity regulating component is effective in maintaining the pH of the implant in a range of about 3 to about 7.
13. (Original) The implant of claim 1, wherein the acidity regulating component is effective in maintaining the pH of the implant in a range of about 4 to about 6.
14. (Original) The implant of claim 1, wherein the acidity regulating component is effective in stabilizing the neurotoxin as the implant biodegrades.

15. (Original) The implant of claim 1, wherein the acidity regulating component is effective in maintaining the neurotoxin in a stabilized form during the life of the implant.
16. (Canceled)
17. (Original) The implant of claim 16, wherein the monomers and oligomers are provided in a range of about 0.1% (w/w) to about 30% (w/w) of the implant.
18. (Previously Presented) The implant of claim 1, wherein the acidity regulating component comprises a combination of monomers and oligomers derived from the same biodegradable polymer.
19. (Original) The implant of claim 17, wherein the biodegradable polymer is selected from the group consisting of polyesters, poly (ortho esters), polyanhydrides, and mixtures thereof.
20. (Original) The implant of claim 17, wherein the biodegradable polymer is selected from the group consisting of poly-lactic acid (PLA), poly (lactide-co-glycolide) acid (PLGA), poly-L-lactic acid (PLLA), polycaprolactone, poly (ortho acetate), and mixtures thereof.
21. (Canceled)
22. (Canceled)
23. (Currently Amended) The implant of claim 1, wherein the biodegradable polymer component includes a first biodegradable polymer, and the acidity regulating component includes a monomer and an oligomer derived from ~~the a~~ a same second biodegradable polymer.

24. (Original) The implant of claim 1, further comprising a pharmaceutically acceptable excipient.
25. (Original) The implant of claim 1, wherein the acidity regulating component comprises monomers from which a biodegradable polymer is derived, and the implant further comprises salts of the monomers.
26. (Canceled)
27. (Original) The implant of claim 26, wherein the neurotoxin component comprises a botulinum toxin type A.
28. (Canceled)
29. (Currently Amended) The implant of claim ~~26~~ 1, wherein the acidity regulating component includes at least one of (i) a first monomer and (ii) an oligomer derived from a second monomer different from the first monomer, and the biodegradable polymer is derived from a third monomer different from both the first and second monomers.
30. (Original) A biodegradable neurotoxin implant, comprising: a neurotoxin component comprising a botulinum toxin type A; a biodegradable polymer component including at least one biodegradable polymer effective in regulating the release of the botulinum toxin type A from the implant; and an acidity regulating component including a monomer and an oligomer derived from the same biodegradable polymer.
31. (Original) The implant of claim 30, wherein the biodegradable polymer component includes a plurality of different biodegradable polymers.
32. (Canceled)
33. (Original) A method of making the implant of claim 30, comprising a step of

blending the neurotoxin component, the biodegradable polymer component, and the acidity regulating component together.

34. (New) A biodegradable neurotoxin implant, comprising: a neurotoxin component associated with; a biodegradable polymer component; and an acidity regulating component effective in establishing in vivo a pH in the vicinity of the neurotoxin component associated with the implant of less than about 7, wherein the acidity regulating component comprises a monomer and an oligomer derived from a different biodegradable polymer.

35. (New) The implant of claim 34, wherein the acidity regulating component comprises a combination of monomers and oligomers derived from a different biodegradable polymer

36. (New) A biodegradable neurotoxin implant, comprising: a neurotoxin component comprising a botulinum toxin type A; a biodegradable polymer component including at least one biodegradable polymer effective in regulating the release of the botulinum toxin type A from the implant; and an acidity regulating component including a monomer and an oligomer derived from a different biodegradable polymer

37. (New) The implant of claim 1, wherein said monomers and oligomers of said acidity regulating component are together about 25%, 20%, 15%, or 0.1% by weight of said biodegradable polymer component.

38. (New) The implant of claim 1, wherein the ratio of said monomers and oligomers of said acidity regulating component is about 60:40, 70:30, 10:90 or 80:20.

39. (New) The implant of claim 1, wherein said monomers and oligomers of said acidity regulating component are together about 25%, 20%, 15%, or 0.1% by weight of said biodegradable polymer component and the ratio of said monomers and oligomers of said acidity regulating component is about 60:40, 70:30, 10:90 or 80:20.